Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?

Anne H Blaes, Evidio Domingo-Musibay, Kevin Kalinsky

Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Apr 15

filter terms:

Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis.See related article by Hiller et al., p. 1803. ©2020 American Association for Cancer Research.

Citation

Anne H Blaes, Evidio Domingo-Musibay, Kevin Kalinsky. Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer? Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Apr 15;26(8):1781-1783